Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00446836 · ClinicalTrials.gov registry record · Phase 2

Efficacy and Safety Study of Xyotax to Treat Prostate Cancer

A Phase 2 study, sponsored by The Methodist Hospital Research Institute.

Completed
Registry status
Phase 2
Development phase
29
Enrollment target

NCT00446836: Completed Phase 2 study, sponsored by The Methodist Hospital Research Institute.

NCT00446836 is a Phase 2 study that has completed, run by The Methodist Hospital Research Institute. The registered enrollment target is 29 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00446836, a Phase 2 study, has completed, sponsored by The Methodist Hospital Research Institute.

COMPLETED
Registry status
Phase 2
Development phase
29 participants
Enrollment target

Study Summary

The purpose of this study is to determine whether Xyotax, a conjugate of the taxane drug paclitaxel, is effective in the treatment of prostate cancer that is no longer responsive to hormone therapy.

Primary Outcome

data from study not available

Interventions

  • DRUG Paclitaxel polyglumex (Xyotax)

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2005-03
Est. Completion 2008-01
Phase Phase 2

What the finished NCT00446836 record still lists

NCT00446836 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower).

The record links to 0 conditions, and to 1 intervention - of which Paclitaxel polyglumex (Xyotax) is the first listed.

NCT00446836 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00446836 about?

NCT00446836 is a clinical study titled "Efficacy and Safety Study of Xyotax to Treat Prostate Cancer". The purpose of this study is to determine whether Xyotax, a conjugate of the taxane drug paclitaxel, is effective in the treatment of prostate cancer that is no longer responsive to hormone therapy.

What is the current status of trial NCT00446836?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2005-03. Estimated completion is 2008-01.

What interventions are being tested in trial NCT00446836?

The interventions under investigation include: Paclitaxel polyglumex (Xyotax) (DRUG).

Who is sponsoring clinical trial NCT00446836?

This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00446836's enrollment target sits among peer trials

29 1669th of 2000 higher than 324 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02429557 · 29 participants · Phase 1

    Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure

  • NCT02568878 · 29 participants · Phase 3

    Creatine for Depressed Male and Female Methamphetamine Users

  • NCT03014401 · 29 participants · NA

    The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis

  • NCT03128996 · 29 participants · Phase 1

    Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00446836, the US trial registry maintained by the National Library of Medicine. NCT00446836 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.